BCDA BioCardia Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCDA

Price (delayed)

$0.3799

Market cap

$10.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.55

Enterprise value

$10.37M

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's ...

Highlights
The debt has declined by 19% year-on-year and by 6% since the previous quarter
The EPS has grown by 18% YoY and by 11% from the previous quarter
The equity has dropped by 143% since the previous quarter and by 133% year-on-year
BCDA's quick ratio has plunged by 85% YoY and by 45% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biocardia.com
Peers: OMER OMGA

Key stats

What are the main financial stats of BCDA
Market
Shares outstanding
26.73M
Market cap
$10.16M
Enterprise value
$10.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
16.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.74
Earnings
Revenue
$477,000
EBIT
-$11.57M
EBITDA
-$11.16M
Free cash flow
-$9.99M
Per share
EPS
-$0.55
Free cash flow per share
-$0.47
Book value per share
-$0.07
Revenue per share
$0.02
TBVPS
$0.14
Balance sheet
Total assets
$2.99M
Total liabilities
$4.59M
Debt
$1.32M
Equity
-$1.6M
Working capital
-$2.15M
Liquidity
Debt to equity
-0.82
Current ratio
0.4
Quick ratio
0.32
Net debt/EBITDA
-0.02
Margins
EBITDA margin
-2,339.6%
Gross margin
100%
Net margin
-2,425.8%
Operating margin
-2,441.1%
Efficiency
Return on assets
-228.6%
Return on equity
-3,638.7%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-2,425.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCDA stock price

How has the BioCardia stock price performed over time
Intraday
-0.03%
1 week
-0.03%
1 month
-3.33%
1 year
-81.01%
YTD
-42.8%
QTD
-6.66%

Financial performance

How have BioCardia's revenue and profit performed over time
Revenue
$477,000
Gross profit
$477,000
Operating income
-$11.64M
Net income
-$11.57M
Gross margin
100%
Net margin
-2,425.8%
BioCardia's operating margin has shrunk by 177% YoY and by 11% QoQ
The net margin has dropped by 175% year-on-year and by 10% since the previous quarter
BioCardia's revenue has plunged by 65% YoY and by 16% from the previous quarter
BioCardia's gross profit has plunged by 65% YoY and by 16% from the previous quarter

Growth

What is BioCardia's growth rate over time

Valuation

What is BioCardia stock price valuation
P/E
N/A
P/B
N/A
P/S
16.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.74
The EPS has grown by 18% YoY and by 11% from the previous quarter
The equity has dropped by 143% since the previous quarter and by 133% year-on-year
BCDA's P/S is 82% below its 5-year quarterly average of 94.0 and 67% below its last 4 quarters average of 50.7
BioCardia's revenue has plunged by 65% YoY and by 16% from the previous quarter

Efficiency

How efficient is BioCardia business performance
The ROS has plunged by 175% YoY and by 10% from the previous quarter
The ROA has plunged by 107% YoY and by 23% from the previous quarter

Dividends

What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCDA.

Financial health

How did BioCardia financials performed over time
BCDA's total assets is 35% lower than its total liabilities
BCDA's quick ratio has plunged by 85% YoY and by 45% from the previous quarter
BCDA's current ratio has shrunk by 82% YoY and by 38% QoQ
The debt is 182% greater than the equity
The equity has dropped by 143% since the previous quarter and by 133% year-on-year
BioCardia's debt to equity has soared by 61% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.